DataLend – Securities Lending Top 10 Earning Equities

DataLend presents its top 10 earnings equities for November 19, 2014. This list is built on DataLend’s universe of more than 42,000 securities on loan.

Methodology: We scan our universe of more than 42,000 securities on loan to find those securities with the most expensive financing positions in the U.S., U.K., Europe and Asia. Financing costs are determined by taking the total on-loan value of a security and multiplying it by the volume-weighted average fees to borrow that security, then converting the product of those numbers to a dollar value. We then sort the most expensive securities to finance in the securities lending market in descending order.

US

Utilization

1 GOPRO CL A 97.62%
2 AMTRUST FINANCIAL SERVICES 92.20%
3 3D SYSTEMS 91.97%
4 MYRIAD GENETICS 92.34%
5 LINDSAY 91.26%
6 BURGER KING WORLDWIDE 91.06%
7 INVENSENSE 92.50%
8 MOBILEYE 91.05%
9 MANNKIND 93.36%
10 SEARS HOLDINGS 85.65%

UK

Utilization

1 SAINSBURY 74.48%
2 MONITISE 63.57%
3 QUINDELL 96.14%
4 ROYAL DUTCH SHELL CL A 14.50%
5 LONMIN 71.75%
6 ASHMORE GROUP 69.41%
7 JSC VTB BANK GDR 44.48%
8 BP 3.35%
9 GULF KEYSTONE PETROLEUM 95.79%
10 AVANTI COMMUNICATIONS GROUP 91.69%

Europe

Utilization

1 GEMALTO (NL) 79.76%
2 SAINSBURYJ (GB) 74.48%
3 SUEDZUCKER MANNHEIM OCHSENFURT (DE) 84.71%
4 ENDESA (ES) 73.05%
5 BOLLORE (FR) 80.19%
6 COMPAGNIE GENERALE GEOPHYSIQUE (FR) 73.84%
7 FIAT CHRYSLER AUTOMOBILES 62.13%
8 TGS NOPEC GEOPHYSICAL (NO) 80.22%
9 GEMALTO (FR) 85.93%
10 NUMERICABLE GROUP 55.01%

Far East/Australia Pacific

Utilization

1 HANERGY TFP (HK) 87.47%
2 EVERGRANDE (HK) 86.08%
3 MIXI (JP) 96.11%
4 CELLTRION (KR) 68.37%
5 GUNGHO ONLINE (JP) 89.64%
6 PRADA (HK) 86.08%
7 SANRIO (JP) 84.33%
8 TIANHE CHEM 86.53%
9 GREE (JP) 82.46%
10 HUISHAN DAIRY 65.44%

Click here for more information about DataLend’s key features.


THE INFORMATION CONTAINED HEREIN IS PROPRIETARY TO EQUILEND; MAY NOT BE COPIED OR DISTRIBUTED WITHOUT THE EXPRESS CONSENT OF EQUILEND; SHALL NOT CONSTITUTE INVESTMENT ADVICE BY EQUILEND, OR ANY REPRESENTATIVE THEREOF; IS NOT WARRANTED TO BE ACCURATE, COMPLETE OR TIMELY; IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY; IS NOT INTENDED FOR TRADING PURPOSES; AND SHOULD NOT BE CONSTRUED AS EQUILEND MAKING FORECASTS, PROJECTING RETURNS OR RECOMMENDING ANY PARTICULAR COURSE OF ACTION. NEITHER EQUILEND NOR ANY REPRESENTATIVE THEREOF SHALL BE AN ADVISOR OR A FIDUCIARY OF A VISITOR TO THIS WEBSITE. EQUILEND IS NOT RESPONSIBLE OR LIABLE IN ANY WAY TO THE READER OR VISITOR, OR TO ANY PERSON, FIRM OR CORPORATION FOR ANY DAMAGES OR LOSSES ARISING FROM ANY USE OF THE INFORMATION CONTAINED HEREIN. IN CONSIDERING THE INFORMATION CONTAINED HEREIN, A VISITOR TO THIS WEBSITE DOES SO SOLELY IN RELIANCE ON THE VISITOR’S OWN JUDGMENT. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE PERFORMANCE.

Related Posts

Previous Post
The Fed’s Tarullo: beefing up liquidity regulation wherever liquidity emerges
Next Post
BNY Mellon and CME set to introduce tri-party indices and futures. Is this the right time?

Fill out this field
Fill out this field
Please enter a valid email address.

X

Reset password

Create an account